Εμφάνιση απλής εγγραφής

dc.creatorBogdanos D.P., Daniil Z., Zakynthinos E., Gourgoulianis K., Sakkas L.I.en
dc.date.accessioned2023-01-31T07:38:44Z
dc.date.available2023-01-31T07:38:44Z
dc.date.issued2020
dc.identifier10.31138/MJR.31.1.94
dc.identifier.issn24593516
dc.identifier.urihttp://hdl.handle.net/11615/71755
dc.description.abstractThe current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece. © Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI.en
dc.language.isoenen
dc.sourceMediterranean Journal of Rheumatologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087843778&doi=10.31138%2fMJR.31.1.94&partnerID=40&md5=a9cb4774d738fe3c45812a77fd765cf0
dc.subjectantivirus agenten
dc.subjectchloroquineen
dc.subjecthydroxychloroquine sulfateen
dc.subjectplaceboen
dc.subjectantiviral activityen
dc.subjectArticleen
dc.subjectcellular immunityen
dc.subjectChinaen
dc.subjectclinical protocolen
dc.subjectcoronavirus disease 2019en
dc.subjectcytokine stormen
dc.subjectdisease courseen
dc.subjectdisease durationen
dc.subjectdisease severityen
dc.subjectdrug contraindicationen
dc.subjectdrug efficacyen
dc.subjectdrug researchen
dc.subjectdrug safetyen
dc.subjectdrug useen
dc.subjectFranceen
dc.subjectGreeceen
dc.subjectGreek (people)en
dc.subjecthealth care systemen
dc.subjecthumanen
dc.subjecthumoral immunityen
dc.subjectintensive care uniten
dc.subjectloading drug doseen
dc.subjectmalariaen
dc.subjectmedical decision makingen
dc.subjectmortalityen
dc.subjectnonhumanen
dc.subjectpandemicen
dc.subjectpatient selectionen
dc.subjectpractice guidelineen
dc.subjectrheumatic diseaseen
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjecttreatment durationen
dc.subjecttreatment outcomeen
dc.subjectunspecified side effecten
dc.subjectvirus pneumoniaen
dc.subjectGreek Rheumatology Society and Professional Association of Rheumatologistsen
dc.titleWhen there is a pandemic there is no time to waste: Should we have hydroxychloroquine in our armoury against COVID-19 infected patients?en
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής